Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.19.3.a.u2
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Expenses        
Research and development $ 712,193 $ 947,249 $ 1,433,668 $ 1,966,369
General and administrative 1,053,747 874,884 1,967,375 1,861,354
Operating expenses 1,765,940 1,822,133 3,401,043 3,827,723
Other (income) loss        
Change in fair value of derivative liability (1,261) (1,041)
Foreign exchange loss 2,254 5,097 1,880 10,935
Interest income (28,143) (16,272) (57,001) (36,116)
Other loss (income) (25,889) (12,436) (55,121) (26,222)
Net loss for the period 1,740,051 1,809,697 3,345,922 3,801,501
Computation of basic loss per share        
Net loss for the period 1,740,051 1,809,697 3,345,922 3,801,501
Series B Preferred stock dividend 2,552 16,190 4,598 52,275
Net loss for the period attributable to common stockholders $ 1,742,603 $ 1,825,887 $ 3,350,520 $ 3,853,776
Basic and fully diluted loss per share $ 0.15 $ 0.75 $ 0.35 $ 1.63
Basic weighted average number of shares 11,407,744 2,424,222 9,473,153 2,360,566